Impact of Adalimumab Patient Support Program’s Care Coach Calls on Clinical Outcomes in Patients with Crohn’s Disease in Canada: An Observational Retrospective Cohort Study

BACKGROUND: Adalimumab is an antitumour necrosis factor (TNFα) biologic therapy indicated for the treatment of Crohn’s disease (CD). Patients receiving adalimumab in Canada are eligible to enroll in the AbbVie Care™ patient support program (AC-PSP), which provides personalized services, including ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Narula, Neeraj, Millson, Brad, Charland, Katia, Donepudi, Krishna, Gaetano, Tania, McHugh, Kevin, Latour, Martin G, Gazel, Sandra, Laliberté, Marie-Claude, Marshall, John K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542296/
https://www.ncbi.nlm.nih.gov/pubmed/31294360
http://dx.doi.org/10.1093/jcag/gwy059

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542296/
https://www.ncbi.nlm.nih.gov/pubmed/31294360
http://dx.doi.org/10.1093/jcag/gwy059

Ejemplares similares